Alirocumab shows promise as treatment to reduce LDL-cholesterol in Phase III study

February 17, 2015, Future Science Group
Credit: Future Science Group

A recently published clinical trial report reviewing the first completed Phase III study in the ODYSSEY development program has shown that alirocumab showed significantly better LDL-C lowering than ezetimibe, with a comparable safety profile to ezetimibe.

The report, which is published in the January issue of Future Cardiology, provides a comprehensive overview of the ODYSSEY MONO trial, including detail on the study design, data analysis, results and discussion on the implications of the findings, authored by lead investigator of the trial Eli M Roth.

LDL-cholesterol (LDL-C) is considered to be a major modifiable risk factor for the development of atherosclerosis and cardiovascular disease (CVD), the leading cause of death worldwide. LDL-C is identified as the primary target of cholesterol-lowering therapy in both North American and European guidelines. Statins are the recommended first-line therapy for lowering LDL-C.

Alirocumab (formerly SAR236553/REGN727) is a fully human mAb to PCSK9 - the first in this class of drugs to complete a Phase III trial, and reported to have a significant role in the regulation of LDL-C - being developed jointly by Sanofi (France) and Regeneron (NY, USA).

This first completed Phase III study, entitled ODYSSEY MONO, tested the new lower 75-mg dose of alirocumab subcutaneously every 2 weeks as a monotherapy versus 10 mg per os every day as a control. Inclusion criteria included patients with an LDL-C between 100 mg/dl (?2.6 mmol/l) and 190 mg/dl (<4.9 mmol/l; inclusive) and not on LLT. In addition, patients needed to have moderate CV risk defined as a 10-year risk of fatal CV events ?1% and <5% based on the European Systematic Coronary Risk Estimation (SCORE).

These data from the study suggest that the 75-mg dose of alirocumab subcutaneously every 2 weeks may be appropriate for adequate lowering of LDL-C in a large portion of patients with primary hypercholesterolemia at moderate CV risk who are not receiving statin therapy.

The safety parameters, adverse events and study discontinuation rates were similar between both treatment arms.

"Since ODYSSEY MONO, we have seen several phase III trials that have confirmed the ability of alirocumab to lower LDL-C in moderate to high risk cardiovascular patients," said Eli M. Roth Medical Director, Sterling Research Group & Professor of Clinical Medicine University of Cincinnati, and lead author of the article published in Future Cardiology. "These completed show that PCSK9 inhibitors are proving to be effective in different patient populations."

Sean Fitzpatrick, Commissioning Editor of Future Cardiology, commented: "Following the presentation of Sanofi/Regeneron's positive top-line results at the end of 2014, we feel it is important for our readers to have a comprehensive, accessible overview of this important topic. The review article helps in providing context for clinicians and researchers framing the results in terms of the current state of the art in lipid-lowering therapy."

Explore further: Investigational agent outshines ezetimibe for lowering cholesterol

More information: Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiology, 2015; 11(1): 27-37

Related Stories

Investigational agent outshines ezetimibe for lowering cholesterol

September 1, 2014
The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease (CVD), ...

Evolocumab safely drops LDL cholesterol well below statin-only baseline

March 31, 2014
The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 ...

Greater drop in LDL seen with atorvastatin plus PCSK9 antibody

November 2, 2012
(HealthDay)—Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein (LDL) cholesterol levels ...

Statins for kidney disease patients: Protection for the heart but no effects on kidneys

May 1, 2014
Lowering LDL cholesterol through statin-based treatment did not slow kidney disease progression within five years in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The ...

Antibody combined with statin results in further reduction of cholesterol levels

May 13, 2014
Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition of the human monoclonal antibody evolocumab resulted in additional lowering of low-density lipoprotein cholesterol (LDL-C) ...

Antibody injection lowers LDL, adding to effectiveness of statin therapy

March 26, 2012
A novel monoclonal antibody identified in a new study dramatically lowered circulating LDL cholesterol by 40 percent to 72 percent, a development with potential to provide a new option for patients who are resistant to cholesterol-lowering ...

Recommended for you

Heart researchers develop a new, promising imaging technique for cardiac arrhythmias

February 22, 2018
Every five minutes in Germany alone, a person dies of sudden cardiac arrest or fibrillation, the most common cause of death worldwide. This is partly due to the fact that doctors still do not fully understand exactly what ...

Scientists use color-coded tags to discover how heart cells develop

February 22, 2018
UCLA researchers used fluorescent colored proteins to trace how cardiomyocytes—cells in heart muscle that enable it to pump blood—are produced in mouse embryos. The findings could eventually lead to methods for regenerating ...

Beetroot juice supplements may help certain heart failure patients

February 22, 2018
Beetroot juice supplements may help enhance exercise capacity in patients with heart failure, according to a new proof-of-concept study. Exercise capacity is a key factor linked to these patients' quality of life and even ...

'Beetroot pill' could help save patients from kidney failure after heart X-ray

February 22, 2018
Beetroot may reduce the risk of kidney failure in patients having a heart x-ray, according to research led by Queen Mary University of London.

Women once considered low risk for heart disease show evidence of previous heart attack scars

February 20, 2018
Women who complain about chest pain often are reassured by their doctors that there is no reason to worry because their angiograms show that the women don't have blockages in the major heart arteries, a primary cause of heart ...

Heart attack symptoms often misinterpreted in younger women

February 20, 2018
Young women who report heart attack symptoms are more likely to have them dismissed by their providers as not heart related, a new study led by the Yale School of Public Health (YSPH) finds.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.